Relmada Therapeutics, Inc. (RLMD)Tuesday said it has appointed Raj S. Pruthi as Chief Medical Officer-Urology (CMO).
Pruthi is a physician-scientist with more than 25 years of experience in industry and academic medicine, specializing in urologic oncology, clinical trials, and robotic surgery. Previously, Pruthi was the Chief Medical Officer at enGene Holdings Inc. He also served as Global Medical Affairs leader at Johnson and Johnson Innovative Medicine.
"As we prepare to begin registrational studies, we believe Raj's extensive clinical experience will play a vital role in the NDV-01 programs success, said Sergio Traversa, Chief Executive Officer, Relmada.
The company had reported positive initial Phase 2 data for its lead drug candidate NDV-01 for the treatment of non-muscle invasive bladder cancer (NMIBC) in April this year. Relmada plans to initiate a Phase 3 study of NDV-01 in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.